Patients who administered at home had a higher rate of adherence (1.85 doses per patient per week) compared to administration at an infusion center (1.40 doses per week) or physicians office (1.40 doses per week). In addition, after the initiation of the training and support program, home administration increased by 61 percent, and an increase was seen across all age groups."Our goal at ViroPharma is to ensure that every patient who is prescribed Cinryze for routine prevention of HAE gets the support they need to optimize their experience," commented Paul Firuta, ViroPharma's vice president and general manager, Americas. "This includes product and disease educational materials as well as self administration training and support through our Path to Independence program."
ViroPharma Presents New Cinryze® (C1 Esterase Inhibitor [human]) Data On Site Of Care And Adherence At The 2012 Academy Of Managed Care Pharmacy Educational Conference
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.